Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases. The company was spawned from the research of Prof. Adriano Aguzzi and his colleagues at the University of Zurich (UZH) and the University Hospital of Zurich (USZ). Human-derived antibodies have superior therapeutic potential compared to antibodies derived from animal models or artificial libraries. In addition, they offer unique opportunities to learn about the target’s human biology and safety profile. However, human antibody reactivity against self-targets is tightly regulated and extremely rare in the general population. To identify these extremely rare human antibodies, Mabylon screens up to 100’000 human serum samples a year for the presence of target-specific antibodies. Through advanced B-cell screening technologies Mabylon identifies, clones, and expresses fully human antibodies, which are then tested for their pre-clinical therapeutic efficacy and clinical developability.